Back HCV Disease Progression Fibrosis/Cirrhosis

Fibrosis & Cirrhosis

Coverage of the 2012 AASLD Liver Meeting coverage of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) in Boston, November 9-13, 2012.

Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.

Full listing by topic AASLD 2012 conference section



AASLD 2012: High Rate of Response to Daclatasvir and Asunaprevir in Harder-to-treat Hep C Patients

Although an interferon-free combination of antiviral drugs developed by Bristol-Myers Squibb (BMS) to treat hepatitis C was highly effective in curing the infection in previous null responders with HCV genotype 1b infection, some new antiviral drugs may still need to be administered with interferon in harder-to-treat patients with genotype 1a, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) in Boston.alt

Read more:

Bacterial Translocation Linked to Severe Liver Disease among HIV/HCV Coinfected People

HIV positive people with hepatitis C coinfection who had evidence of intestinal bacteria in their blood -- known as bacterial translocation -- had more advanced liver fibrosis and faster fibrosis progression, researchers reported in the August 28, 2012, advance edition of the Journal of Acquired Immune Deficiency Syndromes. alt

Read more:

AASLD 2012: Danoprevir and Mericitabine Work for Prior Non-responders, Hep C Patients with Cirrhosis

The experimental hepatitis C drugs danoprevir and mericitabine, with or without pegylated interferon and ribavirin, showed good safety and efficacy in previously treated patients, according to findings from the MATTERHORN study presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston. Another analysis from the same trial showed good outcomes for people with liver fibrosis.alt

Read more:

Hepatitis C Raises Risk of Both Liver-Related and Non-Liver Deaths

Overall mortality from both liver-related disease and non-liver conditions -- including some cancers -- is significantly increased in people with chronic hepatitis C virus (HCV) infection compared with uninfected individuals, according to a study published in the July 17, 2012, advance online edition of the Journal of Infectious Diseases.alt

Read more: